Corrigendum to "Scientific overview: 2013 BBC plenary symposium on tobacco addiction" [Drug Alcohol Depend. 141 (2014) 107-117] DOI: 10.1016/j.drugalcdep.2014.05.013;Scientific overview: 2013 BBC plenary symposium on tobacco addiction

Drug and Alcohol Dependence

Volumn 141, Issue , 2014, Pages 107-117

  De Biasi, M ^a,b   McLaughlin, I ^a   Perez, E E ^b   Crooks, P A ^c   Dwoskin, L P ^d   Bardo, M T ^e   Pentel, P R ^f   Hatsukami, D ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d University of Kentucky   (United States)

^e UNIVERSITY OF KENTUCKY   (United States)

^f UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Nicotine dependence; Nicotine vaccine; Nicotine withdrawal; Nicotinic receptor antagonists; Smoking cessation; Tobacco product regulation

Indexed keywords

DRUGS USED IN THE TREATMENT OF ADDICTION; MECAMYLAMINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY NIC311; N,N' DODECANE 1,12 DIYL BIS 3 PICOLINIUM DIBROMIDE; NANOPARTICLE; NICOTINE; NICOTINE PATCH; NICOTINE VACCINE; NICOTINIC RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CHROMOSOME 15Q; DOSE RESPONSE; DRUG CONJUGATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; GENE CLUSTER; GENE TRANSFER; GENETIC ASSOCIATION; HABENULA; HUMAN; INTERPEDUNCULAR NUCLEUS; MOLECULAR PATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SMOKING; SMOKING CESSATION; SMOKING REGULATION; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VACCINATION; VIRAL GENE DELIVERY SYSTEM; WITHDRAWAL SYNDROME; BEHAVIOR, ADDICTIVE; PATHOPHYSIOLOGY; PROCEDURES; RESEARCH; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

NICOTIANA TABACUM;

BEHAVIOR, ADDICTIVE; HUMANS; RESEARCH; SMOKING; SMOKING CESSATION; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 84903218261     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.09.004     Document Type: Erratum

References (116)

1. Albayati Z.A.F., Dwoskin L.P., Crooks P.A. Pharmacokinetics of the novel nicotinic receptor antagonist N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide in the rat. Drug Metab. Dispos. 2008, 18:3870-3873.
2. Allen S.S., Bade T., Hatsukami D., Center B. Craving, withdrawal, and smoking urges on days immediately prior to smoking relapse. Nicotine Tob. Res. 2008, 10:35-45.
3. Amos C.I., Wu X., Broderick P., Gorlov I.P., Gu J., Eisen T., Dong Q., Zhang Q., Gu X., Vijayakrishnan J., Sullivan K., Matakidou A., Wang Y., Mills G., Doheny K., Tsai Y.Y., Chen W.V., Shete S., Spitz M.R., Houlston R.S. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat. Genet. 2008, 40:616-622.
4. Awate S., Babiuk L.A., Mutwiri G. Mechanisms of action of adjuvants. Front. Immunol. 2013, 4:114.
5. Beckmann, J.S., Meyer, A.C., Pivavarchyk, M., Horton, D.B., Zheng, G., Smith, A.M., McIntosh, M., Crooks, P.A., Bardo, M.T., Dwoskin, L.P., r-bPiDI acts selec- tively at α6β2 nicotinic receptors to decrease nicotine-evoked dopamine release and nicotine reinforcement. Neuropharmacology (under review).
6. Bedi G., Preston K.L., Epstein D.H., Heishman S.J., Marrone G.F., Shaham Y., de Wit H. Incubation of cue-induced cigarette craving during abstinence in human smokers. Biol. Psychiatry 2011, 69:708-711.
7. Benowitz N.L., Henningfield J.E. Establishing a nicotine threshold for addiction. The implications for tobacco regulation. N. Engl. J. Med. 1994, 331:123-125.
8. Benowitz N.L., Hall S.M., Stewart S., Wilson M., Dempsey D., Jacob P. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol. Biomarkers Prev. 2007, 16:8479-8485.
9. Benowitz N.L. Nicotine addiction. N. Engl. J. Med. 2010, 362:2295-2303.
10. Benowitz N.L., Dains K.M., Hall S.M., Stewart S., Wilson M., Dempsey D., Jacob P. Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes. Cancer Epidemiol. Biomarkers Prev. 2012, 21:761-769.
11. Berrettini W., Yuan X., Tozzi F., Song K., Francks C., Chilcoat H., Waterworth D., Muglia P., Mooser V. Alpha-5/alpha-3 nicotinic receptor subunit alleles increase risk for heavy smoking. Mol. Psychiatry 2008, 13:368-373.
12. Bevins R.A., Wilkinson J.L., Sanderson S.D. Vaccines to combat smoking. Expert Opin. Biol. Ther. 2008, 8:379-383.
13. Bierut L.J., Stitzel J.A., Wang J.C., Hinrichs A.L., Grucza R.A., Xuei X., Saccone N.L., Saccone S.F., Bertelsen S., Fox L., Horton W.J., Breslau N., Budde J., Cloninger C.R., Dick D.M., Foroud T., Hatsukami D., Hesselbrock V., Johnson E.O., Kramer J., Kuperman S., Madden P.A., Mayo K., Nurnberger J., Pomerleau O., Porjesz B., Reyes O., Schuckit M., Swan G., Tischfield J.A., Edenberg H.J., Rice J.P., Goate A.M. Variants in nicotinic receptors and risk for nicotine dependence. Am. J. Psychiatry 2008, 165:1163-1171.
14. Brody A.L., Mandelkern M.A., Costello M.R., Abrams A.L., Scheibal D., Farahi J., London E.D., Olmstead R.E., Rose J.E., Mukhin A.G. Brain nicotinic acetylcholine receptor occupancy: effect of smoking a denicotinized cigarette. Int. J. Neuropsychopharmacol. 2009, 12:305-316.
15. Broms U., Wedenoja J., Largeau M.R., Korhonen T., Pitkaniemi J., Keskitalo-Vuokko K., Happola A., Heikkila K.H., Heikkila K., Ripatti S., Sarin A.P., Salminen O., Paunio T., Pergadia M.L., Cai X., Tsuchikama K., Janda K.D. Modulating cocaine vaccine potency through hapten fluorination. J. Am. Chem. Soc. 2013, 135:2971-2974.
16. Carrera M.R., Ashley J.A., Hoffman T.Z., Isomura S., Wirsching P., Koob G.F., Janda K.D. Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg. Med. Chem. 2004, 12:563-570.
17. Centers for Disease Control and Prevention Quitting smoking among adults-United States, 2001-2010. MMWR: Morb. Mortal. Wkly. Rep. 2011, 60:1513-1519.
18. Cornuz J., Zwahlen S., Jungi W.F., Osterwalder J., Klingler K., van Melle G., Bangala Y., Guessous I., Müller P., Willers J., Maurer P., Bachmann M.F., Cerny T. A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008, 3:e2547.
19. 3H]dopamine release by pyridine N-substituted nicotine analogues: a new class of nicotinic antagonist. Drug Dev. Res. 1995, 36:71-82.
20. Crooks P.A., Ayers J.T., Rui X., Sumithran S.P., Grinevich V.P., Wilkins L.W., Deaciuc A.G., Allen D.D., Dwoshkin L.P. Development of subtype-selective nicotinic receptor ligands as receptor antagonists. Bioorg. Med. Chem. Lett. 2004, 14:1869-1874.
21. Crooks P.A., Bardo M.T., Dwoskin L.P. Nicotinic receptor antagonists as treatments for nicotine abuse. Emerging Targets and Therapeutics in the Treatment of Psychostimulant Abuse 2014, Elsevier, New York, NY. L.P. Dwoskin (Ed.).
22. Damaj M.I., Kao W., Martin B.R. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J. Pharmacol. Exp. Ther. 2003, 307:526-534.
23. Dani J.A., Bertrand D. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Ann. Rev. Pharmacol. Toxicol. 2007, 47:699-729.
24. Davis J.A., James J.R., Siegel S.J., Gould T.J. Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J. Neurosci. 2005, 25:8708-8713.
25. De Biasi M. Nicotinic mechanisms in the autonomic control of organ systems. J. Neurobiol. 2002, 53:568-579.
26. De Biasi M., Salas R. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp. Biol. Med. (Maywood) 2008, 233:917-929.
27. De Biasi M., Dani J.A. Reward, addiction, withdrawal to nicotine. Ann. Rev. Neurosci. 2011, 34:105-130.
28. De B.P., Pagovich O.E., Hicks M.J., Rosenberg J.B., Moreno A.Y., Janda K.D., Koob G.F., Worgall Kaminsky S.M., Sondhi D., Crystal R.G. Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity. Hum. Gene Ther. 2013, 24:58-66.
29. de Villiers S., Cornish K.E., Troska A.J., Praveton M., Pentel P.R. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine 2013, (in press).
30. Donny E.C., Jones M. Prolonged exposure to denicotinized cigarettes with or without transdermal nicotine. Drug Alcohol Depend. 2009, 104:23-33.
31. Donny E.C., Taylor T.G., LeSage M.G., Levin M., Buffalari D.M., Joel D., Sved A.F. Impact of tobacco regulation on animal research: new perspectives and opportunities. Nicotine Tob. Res. 2012, 14:1319-1338.
32. 3H]-dopamine uptake into rat striatal slices by quaternary N-methylated nicotine metabolites. Life Sci. 1992, 50:L233-L237.
33. Dwoskin L.P., Smith A.M., Wooters T.E., Zhang Z., Crooks P.A., Bardo M.T. Nicotinic receptor-based therapeutics and candidates for smoking cessation. Biochem. Pharmacol. 2009, 78:732-743.
34. Dwoskin L.P., Sumithran S.P., Zhu J., Deaciuc A.G., Ayers J.T., Crooks P.A. Subtype-selective nicotinic receptor antagonists: potential as tobacco use cessation agents. Bioorg. Med. Chem. Lett. 2004, 14:1863-1867.
35. Epping-Jordan M.P., Watkins S.S., Koob G.F., Markou A. Dramatic decreases in brain reward function during nicotine withdrawal. Nature 1998, 393:76-79.
36. Fahim R.E., Kessler P.D., Kalnik M.W. Therapeutic vaccines against tobacco addiction. Expert Rev. Vaccines 2013, 12:333-342.
37. Flora A.V., Zambrano C.A., Gallego X., Miyamoto J.H., Johnson K.A., Cowan K.A., Stitzel J.A., Ehringer M.A. Functional characterization of SNPs in CHRNA3/B4 intergenic region associated with drug behaviors. Brain Res. 2013, 1529:1-15.
38. Fowler C.D., Kenny P.J. Nicotine aversion: neurobiological mechanisms and relevance to tobacco dependence vulnerability. Neuropharmacology 2014, 76:533-544.
39. Furberg H., Kim Y., Dackor J., Boerwinkle E., Franceshini N., Ardissino D., Bernardinelli L., Mannucci P.M., Mauri F., Merlini P.A., et al. Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat. Genet. 2010, 42:441-447.
40. Gill M.J., Ghee S.M., Harper S.M., See R.E. Inactivation of the lateral habenula reduces anxiogenic behavior and cocaine seeking under conditions of heightened stress. Pharmacol. Biochem. Behav. 2013, 111:24-29.
41. Gotti C., Moretti M., Clementi F., Riganti F., McIntosh J.M., Collins A.C., Marks M.J., Whiteaker P. Expression of nigrostriatal α6-containing nicotinic acetylcholine receptors is selectively reduced, but not eliminated, by β3 subunit gene deletion. Mol. Pharmacol. 2005, 67:2007-2015.
42. Gotti C., Clementi F., Fornari A., Gaimarri A., Guiducci S., Manfredi I., Moretti M., Pedrazzi P., Pucci L., Zoli M. Structural and functional diversity of native brain neuronal nicotinic receptors. Biochem. Pharmacol. 2009, 78:703-711.
43. Gotti C., Guiducci S., Tedesco V., Corbioli S., Zanetti L., Moretti M., Zanardi A., Rimondini R., Mugnaini M., Clementi F., Chiamulera C., Zoli M. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2 receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. J. Neurosci. 2010, 14:5311-5325.
44. Grebenstein P., Burroughs D., Zhang Y., LeSage M.G. Sex differences in nicotine self-administration in rats during progressive unit dose reduction: implications for nicotine regulation policy. Pharm. Biochem. Behav. 2014, 114-115:70-81.
45. Greenbaum L., Lerer B. Differential contribution of genetic variation in multiple brain nicotinic cholinergic receptors to nicotine dependence: recent progress and emerging open questions. Mol. Psychiatry 2009, 14:912-945.
46. Hatsukami D., Perkins K.A., Lesage M.G., Ashley D.L., Henningfield J.E., Benowitz N.L., Backinger C.L., Zeller M. Nicotine reduction revisited: science and future directions. Tob. Control 2010, 19:1-10.
47. Hatsukami D.K., Kotlyar M., Hertsgaard L.A., Zhang Y., Carmella S.G., Jensen J.A., Allen S.S., Shields P.G., Murphy S.E., Stepanov I., Hecht S.S. Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation. Addiction 2010, 105:343-355.
48. Hatsukami D.K., Jorenby D.E., Gonzales D., Rigotti N.A., Glover E.D., Oncken C.A., Tashkin D.P., Reus V.I., Akhavain R.C., Fahim R.E., Kessler P.D., Niknian M., Kalnik M.W., Rennard S.I. Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic. Clin. Pharmacol. Ther. 2011, 89:392-399.
49. Hatsukami D.K., Hertsgaard L.A., Vogel R.I., Jensen J.A., Murphy S.E., Hecht S.S., Carmella S.G., al'Absi M., Joseph A.M., Allen S.S. Reduced nicotine content cigarettes and nicotine patch. Cancer Epidemiol. Biomarkers Prev. 2013, 22:1015-1024.
50. Hicks M.J., Rosenberg J.B., De B.P., Pagovich O.E., Young C.N., Qiu J.P., Kaminsky S.M., Hackett .N.R., Worgall S., Janda K.D., Davisson R.L., Crystal R.G. AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci. Transl. Med. 2012, 4:140ra187.
51. Hoffman A.C., Evans S.E. Abuse potential of non-nicotine tobacco smoke components: acetaldehyde, nornicotine, cotinine, and anabasine. Nicotine Tob. Res. 2013, 15:622-632.
52. Hughes J.R., Higgins S.T., Bickel W.K. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 1994, 89:1461-1470.
53. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., Mukeria A., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
54. Isomura S., Wirsching P., Janda K.D. An immunotherapeutic program for the treatment of nicotine addiction: hapten design and synthesis. J. Org. Chem. 2001, 66:4115-4121.
55. Keyler D.E., Roiko S.A., Benlhabib E., LeSage M.G., St Peter J.V., Stewart S., Fuller S., Le C.T., Pentel P.R. Monoclonal nicotine-specific antibodies reduce nicotine distribution to brain in rats: dose- and affinity-response relationships. Drug Metab. Dispos. 2005, 33:1056-1061.
56. Keyler D.E., Roiko S.A., Earley C.A., Murtaugh M.P., Pentel P.R. Enhanced immunogenicity of a bivalent nicotine vaccine. Int. Immunopharmacol. 2008, 8:1589-1594.
57. Kishimoto T.K. Rational design of a fully synthetic nanoparticle-based vaccine. Second International Conference on Vaccines and Vaccinations 2012.
58. Koob G.F., Volkow N.D. Neurocircuitry of addiction. Neuropsychopharmacology 2010, 35:217-238.
59. Kulak J.M., Nguyen T.A., Olivera B.M., McIntosh J.M. α-Conotoxin MII blocks nicotine-stimulated dopamine release in rat striatal synaptosomes. J. Neurosci. 1997, 17:5263-5270.
60. Kuryatov A., Berrettini W., Lindstrom J. Acetylcholine receptor (AChR) alpha5 subunit variant associated with risk for nicotine dependence and lung cancer reduces (alpha4beta2)alpha5 AChR function. Mol. Pharmacol. 2011, 79:119-125.
61. LeSage M.G., Keyler D.E., Hieda Y., Collins G., Burroughs D., Le C., Pentel P.R. Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats. Psychopharmacology 2006, 184:409-416.
62. LeSage M.G., Keyler D.E., Pentel P.R. Current status of immunologic approaches to treating tobacco dependence: vaccines and nicotine-specific antibodies. AAPS J. 2006, 8:E65-E75.
63. LeSage M.G., Shelley D., Pravetoni M., Pentel P.R. Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. Pharmacol. Biochem. Behav. 2012, 102:157-162.
64. Li M.D., Cheng R., Ma J.Z., Swan G.E. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003, 98:23-31.
65. Lindblom N., de Villiers S.H., Kalayanov G., Gordon S., Johansson A.M., Svensson T.H. Active immunization against nicotine prevents reinstatement of nicotine-seeking behavior in rats. Respiration 2002, 69:254-260.
66. Liu J.Z., Tozzi F., Waterworth D.M., Pillai S.G., Muglia P., Middleton L., Berrettini W., Knouff C.W., Yuan X., Waeber G., et al. Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat. Genet. 2010, 42:436-440.
67. Liu X., Xu Y., Yu T., Clifford C., Liu Y., Yan H., Chang Y. A DNA nanostructure platform for directed assembly of synthetic vaccines. Nano Lett. 2012, 12:4254-4259.
68. Lockman P.R., Geldenhuys W.J., Manda V., Thomas F., Crooks P.A., Dwoskin L.P., Allen D.D. Carrier mediated transport at the blood-brain barrier for the quaternary ammonium nicotinic receptor antagonist, N,N-dodecyl-bis-picolinium bromide (bPiDDB). J. Pharmacol. Exp. Ther. 2008, 324:244-250.
69. Malin D.H., Goyarzu P. Rodent models of nicotine withdrawal syndrome. Handb. Exp. Pharmacol. 2009, 192:401-434.
70. Matyas G.R., Mayorov A.V., Rice K.C., Jacobson A.E., Cheng K., Iyer M.R., Li F., Beck Z., Janda K.D., Alving C.A. Liposomes containing monophosphoryl lipid a: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine 2013, 31:2804-2810.
71. Mathuru A.S., Jesuthasan S. The medial habenula as a regulator of anxiety in adult zebrafish. Front. Neural Circuits 2013, 7:99.
72. Maurer P., Jennings G.T., Willers J., Rohner F., Lindman Y., Roubicek K., Renner W.A., Muller P., Bachmann M.F. A therapeutic vaccine for nicotine dependence: preclinical efficacy, and phase i safety and immunogenicity. Eur. J. Immunol. 2005, 35:2031-2040.
73. McHeyzer-Williams L.J., McHeyzer-Williams M.G. Antigen-specific memory b cell development. Annu. Rev. Immunol. 2005, 23:487-513.
74. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 2011, 12:341-355.
75. Moreno A.Y., Azar M.R., Koob G.F., Janda K.D. Probing the protective effects of a conformationally constrained nicotine vaccine. Vaccine 2012, 30:6665-6670.
76. Neugenbauer N.M., Zhang Z., Crooks P.A., Dwoskin L.P., Bardo M.T. Effect of a novel nicotinic receptor antagonist, N,N-dodecane-1,12-diyl-bis-3-picolinium dibromide (bPiDDB), on nicotine self-administration and hyperactivity in rats. Psychopharmacology 2006, 184:426-434.
77. Paolini M., De Biasi M. Mechanistic insights into nicotine withdrawal. Biochem. Pharmacol. 2011, 82:996-1007.
78. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Delivery Rev. 2008, 60:915-928.
79. Pentel P.R., Dufek M.B., Roiko S.A., Lesage M.G., Keyler D.E. Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats. J. Pharmacol. Exp. Ther. 2006, 317:660-666.
80. Picciotto M.R., Corrigall W.A. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. J. Neurosci. 2002, 22:3338-3341.
81. Piper M.E., Cook J.W., Schlam T.R., Jorenby D.E., Baker T.B. Anxiety diagnoses in smokers seeking cessation treatment: relations with tobacco dependence, withdrawal, outcome and response to treatment. Addiction 2011, 106:418-427.
82. Pravetoni M., Keyler D.E., Pidaparthi R.R., Carroll F.I., Runyon S.P., Murtaugh M.P., Earley C.A., Pentel P.R. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem. Pharmacol. 2012, 83:543-550.
83. Raupach T., Hoogsteder P.H., Onno van Schayck C.P. Nicotine vaccines to assist with smoking cessation: current status of research. Drugs 2012, 72:e1-e16.
84. Ray L.A., Lunny K., Bujarski S., Moallem N., Krull J.L., Miotto K. The effects of varenicline on stress-induced and cue-induced craving for cigarettes. Drug Alcohol Depend. 2013, 131:136-142.
85. Rhee S.H., Hewitt J.K., Young S.E., Corley R.P., Crowley T.J., Stallings M.C. Genetic and environmental influences on substance initiation, use, and problem use in adolescents. Arch. Gen. Psychiatry 2003, 60:1256-1264.
86. Roiko S.A., Harris A.C., Keyler D.E., Lesage M.G., Zhang Y., Pentel P.R. Combined active and passive immunization enhances the efficacy of immunotherapy against nicotine in rats. J. Pharmacol. Exp. Ther. 2008, 325:985-993.
87. Rose J.E. Multiple brain pathways and receptors underlying tobacco addiction. Biochem. Pharmacol. 2007, 74:1263-1270.
88. Rose J.E., Behm F.M., Westman E.C., Kukovich P. Pre-cessation treatment with nicotine skin patch facilitates smoking cessation. Nicotine Tob. Res. 2006, 8:89-101.
89. Saccone S.F., Hinrichs A.L., Saccone N.L., Chase G.A., Konvicka K., Madden P.A., Breslau N., Johnson E.O., Hatsukami D., Pomerleau O., Swan G.E., Goate A.M., Rutter J., Bertelsen S., Fox L., Fugman D., Martin N.G., Montgomery G.W., Wang J.C., Ballinger D.G., Rice J.P., Bierut L.J. Cholinergic nicotinic receptor genes implicated in a nicotine dependence association study targeting 348 candidate genes with 3713 SNPs. Hum. Mol. Genet. 2007, 16:36-49.
90. Saccone N.L., Saccone S.F., Hinrichs A.L., Stitzel J.A., Duan W., Pergadia M.L., Agrawal A., Breslau N., Grucza R.A., Hatsukami D., Johnson E.O., Madden P.A., Swan G.E., Wang J.C., Goate A.M., Rice J.P., Bierut L.J. Multiple distinct risk loci for nicotine dependence identified by dense coverage of the complete family of nicotinic receptor subunit (CHRN) genes. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 2009, 150B:453-466.
91. Saccone N.L., Culverhouse R.C., Schwantes-An T.H., Cannon D.S., Chen X., Cichon S., Giegling I., Han S., Han Y., Keskitalo-Vuokko K., et al. Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet. 2010, 6:e1001053.
92. Salas R., Pieri F., De Biasi M. Decreased signs of nicotine withdrawal in mice null for the β4 nicotinic acetylcholine receptor subunit. J. Neurosci. 2004, 24:10035-10039.
93. Salas R., Main A., Gangitano D., De Biasi M. Decreased withdrawal symptoms but normal tolerance to nicotine in mice null for the alpha7 nicotinic acetylcholine receptor subunit. Neuropharmacology 2007, 53:863-869.
94. Salas R., Sturm R., Boulter J., De Biasi M. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. J. Neurosci. 2009, 29:3014-3018.
95. Salminen O., Murphy K.L., McIntosh J.M., Drago J., Marks M.J., Collins A.C., Grady S.R. Subunit composition and pharmacology of two classes of striatal presynaptic nicotinic acetylcholine receptors mediating dopamine release in mice. Mol. Pharmacol. 2004, 65:1526-1535.
96. Satoskar S.D., Keyler D.E., LeSage M.G., Raphael D.E., Ross C.A., Pentel P.R. Tissue-dependent effects of immunization with a nicotine conjugate vaccine on the distribution of nicotine in rats. Int. Immunopharmacol. 2003, 3:957-970.
97. Schlaepfer I.R., Hoft N.R., Collins A.C., Corley R.P., Hewitt J.K., Hopfer C.J., Lessem J.M., McQueen M.B., Rhee S.H., Ehringer M.A. The chrna5/a3/b4 gene cluster variability as an important determinant of early alcohol and tobacco initiation in young adults. Biol. Psychiatry 2008, 63:1039-1046.
98. Schnoll R.A., Johnson T.A., Lerman C. Genetics and smoking behavior. Curr. Psychiatry Rep. 2007, 9:349-357.
99. Sherva R., Kranzler H.R., Yu Y., Logue M.W., Poling J., Arias A.J., Anton R.F., Oslin D., Farrer L.A., Gelernter J. Variation in nicotinic acetylcholine receptor genes is associated with multiple substance dependence phenotypes. Neuropsychopharmacology 2010, 35:1921-1931.
100. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin. Pharmacol. Ther. 2012, 91:60-70.
101. Smith T.T., Levin M.E., Schassburger R.L., Buffalari D.M., Sved A.F., Donny E.C. Gradual and immediate nicotine reduction result in similar low-dose nicotine self-administration. Nicotine Tob. Res. 2013, 15:1918-1925.
102. Smith A.M., Pivavarchyk M., Wooters T.E., Zhang Z., McIntosh J.M., Crooks P.A., Bardo M.T., Dwoskin L.P. Repeated nicotine increases bPiDDB potency to inhibit nicotine-evoked DA release from rat striatum. Biochem. Pharmacol. 2010, 80:402-409.
103. Tidey J.W., Rohsenow D.J., Kaplan G.B., Swift R.M., Ahnallen C.G. Separate and combined effects of very low nicotine cigarettes and nicotine replacement in smokers with schizophrenia and controls. Nicotine Tob. Res. 2013, 15:121-129.
104. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., Manolescu A., Thorleifsson G., Stefansson H., Ingason A., et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
105. U.S.Department of Health and Human Services The health consequences of smoking: nicotine and addiction. A Report of the Surgeon General 1988, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Center for Health Promotion and Education, Office on Smoking and Health, U.S. Government Printing Office, Rockville, MD.
106. U.S.Department of Health and Human Services The health consequences of smoking-50 years of progress. A Report of the Surgeon General 2014, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, U.S. Government Printing Office, Washington, DC.
107. Wang J.C., Grucza R., Cruchaga C., Hinrichs A.L., Bertelsen S., Budde J.P., Fox L., Goldstein E., Reyes O., Saccone N., Saccone S., Xuei X., Bucholz K., Kuperman S., Nurnberger J., Rice J.P., Schuckit M., Tischfield J., Hesselbrock V., Porjesz B., Edenberg H.J., Bierut L.J., Goate A.M. Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol. Psychiatry 2009, 14:501-510.
108. WHO Study Group on Tobacco Product Regulation Report on the Scientific Basis of Tobacco Product Regulation: Fourth Report of a WHO Study Group 2012, WHO, Geneva.
109. Wickham R., Solecki W., Rathbun L., McIntosh J.M., Addy N.A. Ventral tegmental area α6β2 nicotinic acetylcholine receptors modulate phasic dopamine release in the nucleus accumbens core. Psychopharmacology (Berl.) 2013, 229:73-82.
110. Wise R.A., Rompre P.P. Brain dopamine and reward. Annu. Rev. Psychol. 1989, 40:191-225.
111. Wray J.M., Gass J.C., Tiffany S.T. A systematic review of the relationships between craving and smoking cessation. Nicotine Tob. Res. 2013, 15:1167-1182.
112. Xu W., Gelber S., Orr-Urtreger A., Armstrong D., Lewis R.A., Ou C.N., Patrick J., Role L., De Biasi M., Beaudet A.L. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:5746-5751.
113. Yamaguchi T., Danjo T., Pastan I., Hikida T., Nakanishi S. Distinct roles of segregated transmission of the septo-habenular pathway in anxiety and fear. Neuron 2013, 78:537-544.
114. Zheng G., Sumithran S.P., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Tris-azaaromatic quaternary ammonium salts: novel templates as antagonists at nicotinic receptors mediating nicotine-evoked dopamine release. Bioorg. Med. Chem. Lett. 2007, 17:6701-6706.
115. Zhang Z., Zheng G., Pivavarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Tetrakis-azaaromatic quaternary ammonium salts: novel subtype-selective antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg. Med. Chem. Lett. 2008, 18:5753-5757.
116. Zhang Z., Zheng G., Pivavarchyk M., Deaciuc A.G., Dwoskin L.P., Crooks P.A. Novel bis-, tris-, and tetrakis-tertiary amino analogs as antagonists at neuronal nicotinic receptors that mediate nicotine-evoked dopamine release. Bioorg. Med. Chem. Lett. 2011, 21:88-91.